BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 208 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $448,000 | +21.1% | 35,000 | 0.0% | 0.10% | +23.8% |
| Q2 2022 | $370,000 | -35.0% | 35,000 | 0.0% | 0.08% | -28.6% |
| Q1 2022 | $569,000 | +17.3% | 35,000 | 0.0% | 0.11% | +25.8% |
| Q4 2021 | $485,000 | +35.1% | 35,000 | +40.0% | 0.09% | +27.1% |
| Q3 2021 | $359,000 | -54.8% | 25,000 | -50.0% | 0.07% | -56.8% |
| Q2 2021 | $794,000 | +56.0% | 50,000 | 0.0% | 0.16% | +50.0% |
| Q1 2021 | $509,000 | -38.1% | 50,000 | -54.5% | 0.11% | -42.2% |
| Q4 2020 | $822,000 | +8.0% | 110,010 | -50.4% | 0.19% | +6.9% |
| Q3 2020 | $761,000 | -14.1% | 221,629 | +19.2% | 0.18% | +4.2% |
| Q2 2020 | $886,000 | – | 185,929 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |